All In Biotech

Drug Trial Radar · NCT00281515

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

An Open-label, Multicenter, Randomized Phase II Study to Compare the Effects of Paclitaxel/Carboplatin and Lonafarnib to Those of Paclitaxel/Carboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV

Last checked: Nov 19, 2026Latest source record: Jun 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 2006

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
AGO Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

  • LonafarnibDrug

    100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: every 3 months until PD

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde

    Berlin, Germany

  • Klinikum Bremen Mitte, Frauenklinik

    Bremen, Germany

  • Carl-Gustav-Carus der TU Dresden, Universitäts-Frauenklinik

    Dresden, Germany

  • Ev. Krankenhaus, Frauenklinik

    Düsseldorf, Germany

  • Klinik für Frauenheilkunde der Univ. Erlangen

    Erlangen, Germany

  • Universitätsfrauenklinik

    Essen, Germany

  • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Frauenheilkunde u. Geburtshilfe

    Frankfurt, Germany

  • Universitätsklinikum Freiburg, Frauenklinik

    Freiburg im Breisgau, Germany

  • Kreiskrankenhaus, Frauenklinik

    Gifhorn, Germany

  • Klinik u. Poliklinik für Gynäkologie und Geburtshilfe

    Greifswald, Germany

  • Medizinische Hochschule

    Hanover, Germany

  • St. Vincentius-Krankenhäuser

    Karlsruhe, Germany

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe

    Kiel, Germany

  • Klinik der Otto-von-Guericke Universität, Frauenklinik

    Magdeburg, Germany

  • Johannes-Gutenberg-Universität, Universitäts-Frauenklinik

    Mainz, Germany

  • Klinikum der Philipps-Universität Marburg, Klinik für Gynäkologie, Gynäkologische Endokrinologie

    Marburg, Germany

  • Klinikum Großhadern, Frauenklinik

    München, Germany

  • Klinikum rechts der Isar der TU München

    München, Germany

  • Elblandkliniken, Frauenklinik

    Radebeul, Germany

  • Klinikum Südstadt

    Rostock, Germany

  • Universitäts-Frauenklinik

    Tübingen, Germany

  • Universitätsfrauenklinik

    Ulm, Germany

  • Dr. Horst Schmidt Klinik, Gynäkologie u. Gynäkologische Onkologie

    Wiesbaden, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.